ID

35188

Descripción

A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02361086

Link

https://clinicaltrials.gov/show/NCT02361086

Palabras clave

Versiones (1)
  1. 22/2/19 22/2/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

22 de febrero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Castration-resistant Prostate Cancer NCT02361086

Inglés

Eligibility Castration-resistant Prostate Cancer NCT02361086

1 formularios  
Criteria
Descripción

Criteria

patients must have documented histological or cytological evidence of adenocarcinoma of the prostate.
Descripción

Adenocarcinoma of prostate

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007112
patients must have a minimum serum psa level of >2 ng/ml that is rising based on the prostate cancer working group 2 criteria.
Descripción

Serum Prostate Specific Antigen Increased

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1883014
patients must have castrate levels of testosterone (<50 ng/dl [1.74 nmol/l]).
Descripción

Testosterone measurement Castration Level

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0523912
UMLS CUI [1,2]
C0007344
UMLS CUI [1,3]
C0441889
patients must have undergone orchiectomy, or have been on lhrh agonists or antagonists, for at least 3 months prior to study entry. patients on lhrh agonists/antagonists must remain on these agents for the duration of the study.
Descripción

Orchiectomy | Luteinizing Hormone-releasing Hormone Agonist | LHRH antagonists

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0029189
UMLS CUI [2]
C1518041
UMLS CUI [3,1]
C0023610
UMLS CUI [3,2]
C0243076
patients must have an ecog performance score of 0 or 1.
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
key exclusion criteria:
Descripción

Exclusion Criteria Main

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C1542147
patients who have received prior cytotoxic chemotherapy for castration-resistant prostate cancer unless enrolled in a previous chemotherapy cohort.
Descripción

Cytotoxic Chemotherapy Castration-Resistant Prostatic Cancer

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0677881
UMLS CUI [1,2]
C3658266
patients who have received second-line antihormonal therapy, including ketoconazole, aminoglutethimide, or high-dose estrogen within 30 days of study entry.
Descripción

Second line Antihormone Therapy | Ketoconazole | Aminoglutethimide | Estrogens High dose

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1710038
UMLS CUI [1,2]
C2986607
UMLS CUI [2]
C0022625
UMLS CUI [3]
C0002555
UMLS CUI [4,1]
C0014939
UMLS CUI [4,2]
C0444956
patients who have completed sipuleucel-t (provenge ®) treatment within 30 days of study entry.
Descripción

sipuleucel-T | Provenge

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1706668
UMLS CUI [2]
C1135133
patients who have received tok-001 (galeterone®) or any other investigational product directed towards the androgen receptor or androgen biosynthesis.
Descripción

TOK-001 | Galeterone | Investigational New Drugs Targeted Androgen Receptor | Investigational New Drugs Targeted Androgen biosynthesis

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2830126
UMLS CUI [2]
C1569219
UMLS CUI [3,1]
C0013230
UMLS CUI [3,2]
C1521840
UMLS CUI [3,3]
C0034786
UMLS CUI [4,1]
C0013230
UMLS CUI [4,2]
C1521840
UMLS CUI [4,3]
C1157302
patients who have received antiandrogens such as flutamide (eulexin®), bicalutamide (casodex®), or nilutamide (nilandron®) for > 3 months must be off treatment for 6 weeks and demonstrate a continued rise in psa after withdrawal. patients on antiandrogens for < 3 months must be off medication for 2 weeks. patients on 5 alpha reductase inhibitors such as finasteride (proscar®, propecia®), or dutasteride (avodart®) must stop medication at least 3 months from study entry.
Descripción

Androgen Antagonists | Flutamide | Eulexin | bicalutamide | Casodex | nilutamide | Nilandron | 5-alpha Reductase Inhibitors To be stopped | Finasteride | Proscar | Propecia | Dutasteride | Avodart

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0002842
UMLS CUI [2]
C0016384
UMLS CUI [3]
C0591412
UMLS CUI [4]
C0285590
UMLS CUI [5]
C0591237
UMLS CUI [6]
C0068771
UMLS CUI [7]
C0722107
UMLS CUI [8,1]
C2936788
UMLS CUI [8,2]
C1272691
UMLS CUI [9]
C0060389
UMLS CUI [10]
C0678149
UMLS CUI [11]
C0722858
UMLS CUI [12]
C0754659
UMLS CUI [13]
C1170079
patients who require pharmacological or replacement doses of systemic corticosteroids or who have received systemic corticosteroids within 30 days of study entry; use of topical, inhaled or ophthalmic steroids is permitted.
Descripción

CORTICOSTEROIDS FOR SYSTEMIC USE | Topical steroids allowed | Inhaled steroids allowed | Ophthalmic steroids allowed

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3653708
UMLS CUI [2,1]
C2064827
UMLS CUI [2,2]
C0683607
UMLS CUI [3,1]
C2065041
UMLS CUI [3,2]
C0683607
UMLS CUI [4,1]
C2013080
UMLS CUI [4,2]
C0683607
patients who have received palliative radiotherapy within 4 weeks of study entry.
Descripción

Palliative Radiation Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3898008
patients with a history within the last 3 years of another invasive malignancy.
Descripción

Cancer Other Invasive

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1707251
UMLS CUI [1,2]
C0205281
Volver a la parte superior de la página

Similar models

Eligibility Castration-resistant Prostate Cancer NCT02361086

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Adenocarcinoma of prostate
Item
patients must have documented histological or cytological evidence of adenocarcinoma of the prostate.
boolean
C0007112 (UMLS CUI [1])
Serum Prostate Specific Antigen Increased
Item
patients must have a minimum serum psa level of >2 ng/ml that is rising based on the prostate cancer working group 2 criteria.
boolean
C1883014 (UMLS CUI [1])
Testosterone measurement Castration Level
Item
patients must have castrate levels of testosterone (<50 ng/dl [1.74 nmol/l]).
boolean
C0523912 (UMLS CUI [1,1])
C0007344 (UMLS CUI [1,2])
C0441889 (UMLS CUI [1,3])
Orchiectomy | Luteinizing Hormone-releasing Hormone Agonist | LHRH antagonists
Item
patients must have undergone orchiectomy, or have been on lhrh agonists or antagonists, for at least 3 months prior to study entry. patients on lhrh agonists/antagonists must remain on these agents for the duration of the study.
boolean
C0029189 (UMLS CUI [1])
C1518041 (UMLS CUI [2])
C0023610 (UMLS CUI [3,1])
C0243076 (UMLS CUI [3,2])
ECOG performance status
Item
patients must have an ecog performance score of 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Exclusion Criteria Main
Item
key exclusion criteria:
boolean
C0680251 (UMLS CUI [1,1])
C1542147 (UMLS CUI [1,2])
Cytotoxic Chemotherapy Castration-Resistant Prostatic Cancer
Item
patients who have received prior cytotoxic chemotherapy for castration-resistant prostate cancer unless enrolled in a previous chemotherapy cohort.
boolean
C0677881 (UMLS CUI [1,1])
C3658266 (UMLS CUI [1,2])
Second line Antihormone Therapy | Ketoconazole | Aminoglutethimide | Estrogens High dose
Item
patients who have received second-line antihormonal therapy, including ketoconazole, aminoglutethimide, or high-dose estrogen within 30 days of study entry.
boolean
C1710038 (UMLS CUI [1,1])
C2986607 (UMLS CUI [1,2])
C0022625 (UMLS CUI [2])
C0002555 (UMLS CUI [3])
C0014939 (UMLS CUI [4,1])
C0444956 (UMLS CUI [4,2])
sipuleucel-T | Provenge
Item
patients who have completed sipuleucel-t (provenge ®) treatment within 30 days of study entry.
boolean
C1706668 (UMLS CUI [1])
C1135133 (UMLS CUI [2])
TOK-001 | Galeterone | Investigational New Drugs Targeted Androgen Receptor | Investigational New Drugs Targeted Androgen biosynthesis
Item
patients who have received tok-001 (galeterone®) or any other investigational product directed towards the androgen receptor or androgen biosynthesis.
boolean
C2830126 (UMLS CUI [1])
C1569219 (UMLS CUI [2])
C0013230 (UMLS CUI [3,1])
C1521840 (UMLS CUI [3,2])
C0034786 (UMLS CUI [3,3])
C0013230 (UMLS CUI [4,1])
C1521840 (UMLS CUI [4,2])
C1157302 (UMLS CUI [4,3])
Androgen Antagonists | Flutamide | Eulexin | bicalutamide | Casodex | nilutamide | Nilandron | 5-alpha Reductase Inhibitors To be stopped | Finasteride | Proscar | Propecia | Dutasteride | Avodart
Item
patients who have received antiandrogens such as flutamide (eulexin®), bicalutamide (casodex®), or nilutamide (nilandron®) for > 3 months must be off treatment for 6 weeks and demonstrate a continued rise in psa after withdrawal. patients on antiandrogens for < 3 months must be off medication for 2 weeks. patients on 5 alpha reductase inhibitors such as finasteride (proscar®, propecia®), or dutasteride (avodart®) must stop medication at least 3 months from study entry.
boolean
C0002842 (UMLS CUI [1])
C0016384 (UMLS CUI [2])
C0591412 (UMLS CUI [3])
C0285590 (UMLS CUI [4])
C0591237 (UMLS CUI [5])
C0068771 (UMLS CUI [6])
C0722107 (UMLS CUI [7])
C2936788 (UMLS CUI [8,1])
C1272691 (UMLS CUI [8,2])
C0060389 (UMLS CUI [9])
C0678149 (UMLS CUI [10])
C0722858 (UMLS CUI [11])
C0754659 (UMLS CUI [12])
C1170079 (UMLS CUI [13])
CORTICOSTEROIDS FOR SYSTEMIC USE | Topical steroids allowed | Inhaled steroids allowed | Ophthalmic steroids allowed
Item
patients who require pharmacological or replacement doses of systemic corticosteroids or who have received systemic corticosteroids within 30 days of study entry; use of topical, inhaled or ophthalmic steroids is permitted.
boolean
C3653708 (UMLS CUI [1])
C2064827 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
C2065041 (UMLS CUI [3,1])
C0683607 (UMLS CUI [3,2])
C2013080 (UMLS CUI [4,1])
C0683607 (UMLS CUI [4,2])
Palliative Radiation Therapy
Item
patients who have received palliative radiotherapy within 4 weeks of study entry.
boolean
C3898008 (UMLS CUI [1])
Cancer Other Invasive
Item
patients with a history within the last 3 years of another invasive malignancy.
boolean
C1707251 (UMLS CUI [1,1])
C0205281 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial